Will Biotelemetry Inc (NASDAQ:BEAT) Run Out of Steam Soon? Short Interest is Up

BioTelemetry, Inc. (NASDAQ:BEAT) Logo

Investors sentiment decreased to 1.04 in 2018 Q2. Its down 0.34, from 1.38 in 2018Q1. It dived, as 12 investors sold BioTelemetry, Inc. shares while 80 reduced holdings. 39 funds opened positions while 57 raised stakes. 29.62 million shares or 0.63% more from 29.44 million shares in 2018Q1 were reported.
Mckinley Cap Limited Delaware holds 4,056 shares or 0.01% of its portfolio. Thompson Davis And accumulated 2,650 shares. Louisiana State Employees Retirement invested 0.03% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT). Bnp Paribas Arbitrage owns 3,592 shares or 0% of their US portfolio. Strs Ohio holds 0.02% or 95,000 shares in its portfolio. Virginia Retirement Et Al owns 20,300 shares. Arrowmark Colorado Holdings Ltd Liability reported 362,457 shares stake. Dafna Cap Management Limited Liability invested in 54,500 shares or 1.15% of the stock. Savings Bank Of America Corp De has 0% invested in BioTelemetry, Inc. (NASDAQ:BEAT) for 228,069 shares. Castleark Mngmt Ltd Limited Liability Company has 304,721 shares for 0.42% of their portfolio. Prelude Cap Mngmt Llc owns 55,431 shares. Guggenheim Capital Limited Liability Corporation has 0.01% invested in BioTelemetry, Inc. (NASDAQ:BEAT). Regions Finance Corp holds 8,254 shares. Morgan Stanley has 263,619 shares. Moreover, Walleye Trading Llc has 0% invested in BioTelemetry, Inc. (NASDAQ:BEAT).

The stock of Biotelemetry Inc (NASDAQ:BEAT) registered an increase of 4.46% in short interest. BEAT’s total short interest was 2.73 million shares in December as published by FINRA. Its up 4.46% from 2.61 million shares, reported previously. With 307,200 shares average volume, it will take short sellers 9 days to cover their BEAT’s short positions. The short interest to Biotelemetry Inc’s float is 8.53%.

The stock decreased 1.83% or $1.25 during the last trading session, reaching $66.95. About 197,172 shares traded. BioTelemetry, Inc. (NASDAQ:BEAT) has risen 55.22% since December 6, 2017 and is uptrending. It has outperformed by 39.60% the S&P500.

BioTelemetry, Inc. provides cardiac monitoring, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The company has market cap of $2.23 billion. The firm operates in three divisions: Healthcare, Research, and Technology. It has a 140.65 P/E ratio. The Healthcare segment focuses on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders.

BioTelemetry, Inc. (NASDAQ:BEAT) Ratings Coverage

Among 2 analysts covering BioTelemetry (NASDAQ:BEAT), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioTelemetry had 3 analyst reports since June 20, 2018 according to SRatingsIntel. As per Wednesday, October 31, the company rating was maintained by Raymond James. Raymond James maintained it with “Outperform” rating and $66 target in Friday, September 14 report.

More notable recent BioTelemetry, Inc. (NASDAQ:BEAT) news were published by: Nasdaq.com which released: “Comstock (CRK) Q3 Earnings Beat, Helped by Production Surge – Nasdaq” on November 19, 2018, also Nasdaq.com with their article: “Dollar Tree (DLTR) Q3 Earnings Beat, Stock Drops on View Cut – Nasdaq” published on November 29, 2018, Nasdaq.com published: “Beat the Market with Pure Style ETFs – Nasdaq” on November 09, 2018. More interesting news about BioTelemetry, Inc. (NASDAQ:BEAT) were released by: Nasdaq.com and their article: “Hewlett Packard (HPE) to Post Q4 Earnings: A Beat in Store? – Nasdaq” published on November 16, 2018 as well as Nasdaq.com‘s news article titled: “Signet (SIG) Expected to Beat Earnings Estimates: Should You Buy? – Nasdaq” with publication date: November 29, 2018.

BioTelemetry, Inc. (NASDAQ:BEAT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.